ATYR PHARMA INC (ATYR)
Sector: Health Care
Sector: Health Care
Compensation data for top executives (showing up to 3 years of data)
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Sanjay S. Shukla, M.D., M.S. President and CEO | 2025 | $638,977 | $0 | $0 | $2,595,200 | $210,862 | $11,214 | $3,456,253 |
| 2024 | $580,887 | $0 | $0 | $641,760 | $246,877 | $10,998 | $1,480,522 | |
| 2023 | $561,243 | $0 | $0 | $532,341 | $196,435 | $10,506 | $1,300,525 |
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Jill M. Broadfoot Chief Financial Officer | 2025 | $471,790 | $0 | $0 | $713,680 | $113,229 | $11,214 | $1,309,913 |
| 2024 | $428,899 | $0 | $0 | $160,440 | $145,826 | $10,998 | $746,163 | |
| 2023 | $414,395 | $0 | $0 | $133,084 | $116,031 | $14,327 | $677,837 |
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Nancy E. Denyes General Counsel | 2025 | $451,570 | $0 | $0 | $713,680 | $108,377 | $11,214 | $1,284,841 |
| 2024 | $410,517 | $0 | $0 | $160,440 | $139,576 | $18,772 | $729,305 | |
| 2023 | $396,635 | $0 | $0 | $133,084 | $111,058 | $10,506 | $651,283 |